Biolase Technology Given New $7.00 Price Target at Northland Capital (BLTI)
Analysts at Northland Capital lifted their price target on shares of Biolase Technology (NASDAQ: BLTI) from $6.00 to $7.00 in a research report issued to clients and investors on Thursday. The firm currently has an “outperform” rating on the stock.
BIOLASE Technology Inc. is a medical technology company. The Company designs, manufactures and markets dental, cosmetic and surgical lasers and related products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.